Syneos Health™ is the industry’s only true end-to-end, fully integrated biopharmaceutical solutions company. At Syneos Health, all the disciplines involved in bringing new therapies to market, from clinical to commercial, work together to create customer success. Our unique Biopharmaceutical Acceleration Model delivers value across the small to mid-size to large customer continuum.
Biopharmaceutical Acceleration Model
It happens when clinical and commercial work hand-in-hand together. When the walls between disciplines come down and are replaced by the sharing of critical insights and data to optimize your success. When everyone in the company begins their work with the ultimate end in mind. Biopharmaceutical acceleration is changing the game and it’s happening here.
Faster processes, deeper insights, smoother systems and more actionable Real World Evidence are just some of the benefits Syneos Health and biopharmaceutical acceleration can bring to a marketplace that grows increasingly complex and competitive each day.
3201 Beechleaf Court Suite 600
Raleigh, NC 27604-1547
Phone: 919 876 9300
Fax: 919 876 9360
The percentage of oncology patients participating in clinical trials is remarkably low: 8.1 percent according to a recent meta-analysis. Read a new report from Syneos Health that shares how enrollment rates and study timelines can be vastly improved by understanding the patient pathway and working to meet patients where they are as they travel along it. The report shares actionable insights for how to meet patients at the right point in their journey – from understanding the influence of emotional pathways of the patient to selecting and priming sites.
Caregivers are an integral part of the care team and are involved in everything from medication choice to adherence strategy. Yet, they’ve often been an afterthought for life sciences companies, even as the industry focuses on patient centricity.
How are consumers engaging with their healthcare in today’s environment and what drives engagement, and what hinders motivation or ability to engage? This study explores these questions.
Life science leaders need ideas and insights to help them invest and act with confidence. Discover 10 macro trends shaping the healthcare industry in the year ahead. Download the 2019 Health Trend Ten eBook.
A longitudinal analysis of PD study characteristics provides a deeper understanding of clinical trials dynamics and demonstrate how research paradigms have been changing across the years.
There is a significant need to collect Real World Evidence (RWE) to demonstrate the benefit of these drugs in clinical practice which can then be used as the wrap around to demonstrate true clinical benefit and address all stakeholder needs.
Questions and concerns as the FDA prepares to develop and implement a program evaluating the potential use of Real World Evidence (RWE) for regulatory decisions.
Are studies focusing on elderly cancer patients at increased risk for discontinuation due to safety reasons, such as toxicity?
Vendor-selection processes are tilting toward finding as broad and deep a fit as possible, the better to capture the efficiencies from scale and repeatability that those moves are intended to deliver.
Successful regulatory approval requires a deep understanding of the regulations, process and technical standards, as well as an appropriate regulatory strategy.